• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

The Market Herald

Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study

8 July 2022 News & MediaThe Market Herald

Neurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).

Neurotech International (ASX:NTI) sees preclinical success with combination therapies

9 June 2022 News & MediaThe Market Herald

Neurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.

Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO

3 March 2022 News & MediaThe Market Herald

Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.

From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream

18 August 2021 News & MediaThe Market Herald

Explore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.

Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains

3 July 2020 News & MediaThe Market Herald

Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.

The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1675266905anoit1675266905anret1675266905nihce1675266905torue1675266905n@ofn1675266905i1675266905

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus